- Home
- JLL vs INSM Comparison
JLL vs INSM Comparison
Compare JLL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | INSM |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 41.2B |
| IPO Year | 1997 | 2000 |
Fundamental Metrics
Financial Performance| Metric | JLL | INSM |
|---|---|---|
| Price | $340.99 | $176.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $342.14 | $185.84 |
| AVG Volume (30 Days) | 325.6K | ★ 3.7M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.91 | N/A |
| EPS | ★ 13.05 | N/A |
| Revenue | ★ $25,317,800,000.00 | $447,022,000.00 |
| Revenue This Year | $11.62 | $43.95 |
| Revenue Next Year | $7.13 | $130.35 |
| P/E Ratio | $26.59 | ★ N/A |
| Revenue Growth | 12.51 | ★ 30.34 |
| 52 Week Low | $194.36 | $60.40 |
| 52 Week High | $347.52 | $212.75 |
Technical Indicators
Market Signals| Indicator | JLL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 39.37 |
| Support Level | $330.62 | $172.65 |
| Resistance Level | $347.52 | $179.44 |
| Average True Range (ATR) | 7.95 | 6.58 |
| MACD | 0.42 | -2.69 |
| Stochastic Oscillator | 78.27 | 34.58 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.